Status | Study |
Recruiting |
Study Name: Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment Condition: Liver Fibroses HepatoCellular Carcinoma Date: 2016-12-21 Interventions: Other: Observation only |
Recruiting |
Study Name: Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Condition: Cryoglobulinemic Vasculitis (CV) Drug-induced Vasculitis E Date: 2016-12-20 |
Recruiting |
Study Name: Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis Condition: Vasculitis Cryoglobulinemia H Date: 2016-07-19 Interventions: Drug: new antiviral therapy |
Recruiting |
Study Name: Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia Condition: Hepatitis C Cryoglobulinemia Date: 2016-07-03 Interventions: Drug: Harvoni 12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 we |
Recruiting |
Study Name: Vasculitis Pregnancy Registry Condition: Vasculitis Behcet's Disease CNS Vasculitis Date: 2015-10-26 Interventions: Other: Online questionnaires Women will be asked to complete questionnaires during their pregnancy and a |
Recruiting |
Study Name: Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis Condition: Cryoglobulinemia Systemic Vasculitis Date: 2015-07-20 Interventions: Drug: rituximab Prednisone tre |
Completed |
Study Name: Impact of Vasculitis on Employment and Income Condition: Vasculitis Systemic Vasculitis Behcet's Disease Date: 2015-06-12 Interventions: Other: online questionnaire The online questionnaire includes questions about vasculitis, employment and |
Completed |
Study Name: The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders Condition: Pemphigus Auto-immune Thrombocytopenic Purpura Hemolytic A Date: 2009-07-16 Interventions: Drug: Rituximab (MABTHERA® or RITUXAN®). patients can be included in the study whatever the do |
Completed |
Study Name: Evaluation of Clinical Efficacy and Immunologic Response After IL-2 Therapy in HCV-related Vasculitis Patients Condition: Cryoglobulinemia Vasculitis Date: 2007-12-14 Interventions: Drug: Proleukin 3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W |
Completed |
Study Name: Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis Condition: Hepatitis C Vasculitis Date: 2002-01-05 Interventions: Drug: Rituximab anti-CD20 monoclonal antibody |